Providence, RI
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)The Institute for Therapeutic Discovery Inc, founded in 2003, is a micro nonprofit that reported $43K in total revenue in fiscal year 2020. Revenue fell 47% from the prior year — a significant decline worth monitoring.
SEE PART 1 LINE 1. TARGETED INDICATIONS INCLUDE CHRONIC CNS DISORDERS. ADDITIONALLY WE HAVE ESTABLISHED THE INSTITUTE FOR CHRONIC TRAUMATIC BRAIN INJURY, llc, A DISREGARDED ENTITY FOR TAX PURPOSES, TO ENABLE DONORS TO FOCUS CONTRIBUTIONS TOWARD THIS CONDITION.
We had very little activity at the Institute for Chronic Traumatic Brain Injury, LLC ICTBI which is a disregarded entity for tax purposes. The COVID-19 pandemic limited our outreadh and face-to-face...
We had very little activity at the Institute for Chronic Traumatic Brain Injury, LLC ICTBI which is a disregarded entity for tax purposes. The COVID-19 pandemic limited our outreadh and face-to-face contacts. Our purpose remains to support product developers or companies with promising products for long-term, chronic traumatic brain injury 1 to complete the research necessary to obtain an IND from the FDA to engage in human clinical trials and 2 to complete their first such trial. Financial support for these activities will be provided by making Mission Related Investments in such projects either for shares or royalties or similar interests and will not generally be provided by making only grants. For many projects or companies the purchase of shares or royalty interests is financially equivalent to grant support. While we do not classify such Mission Related Investments as grants, the reader should recognize that in the year ending 2020 we made an investment of 50,000 in furtherance of this program.
Our continuing program for the discovery and early stage research of useful medicinal compounds by bridging biophysics and biochemistry continues as it has since our founding. The goal of this...
Our continuing program for the discovery and early stage research of useful medicinal compounds by bridging biophysics and biochemistry continues as it has since our founding. The goal of this program has been to help medical practitioners treat disease by restoring natural function at the cellular level with a focus on chronic CNS disorders. The practitioner group continues to meet as it has since the founding of the institute. Our royalty revenue arises from this work.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2020 | 2019 | Change | |
|---|---|---|---|
| Revenue | $43,374 | $81,391 | -0.5% |
| Expenses | $46,189 | $48,831 | -0.1% |
| Net Income | $-2,815 | $32,560 | -1.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Dr Kara Fitzgerald | Director | 000.10 |
Director
|
$0 | $0 | $0 |
| Dr Lloyd Saberski | Director | 000.10 |
Director
|
$0 | $0 | $0 |
| Dr Betty Sadaniantz | Director | 000.10 |
Director
|
$0 | $0 | $0 |
| Dr John McMichael | Chief Exec Officer | 005.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2021 | $43,374 | $46,189 | $51,040 | $-2,815 |
| 2018 | $240,823 | $204,450 | $1,989 | $36,373 |
Compare The Institute for Therapeutic Discovery Inc with other nonprofits in Rhode Island and across the country.